In this post-hoc analysis of the SURMOUNT-1 trial, there was a mostly linear relationship between percentage change in weight ...

1. Median overall survival was 13.6 months in the tarlatamab group and 8.3 months in the chemotherapy group, with HR 0.60 (significant) 2. Adverse events grade 3 or higher occurred in 54% of the ...

Reductions in pain catastrophizing are more closely associated with improvements in emotional functioning than with pain ...

For patients with facet-mediated spine pain that achieve ≥80% pain relief after a medial branch block, a second diagnostic ...

Routine single-session screening for emotional and cognitive issues post-stroke does not improve long-term societal ...

AI-assisted electrocardiogram (ECG) improves early detection of low ejection fraction in hospitalized patients by enhancing ...

Liang and colleagues retrospectively compared Generative Pretrained Transformer 4 (GPT-4)’s comments on scientific papers to ...